Image source: Sarepta Therapeutics, Inc.
What: After failing to win support from a key FDA advisory committee in April, investors shrugged off worries, and sent shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) soaring 47.5% in May, according to S&P Global Market Intelligence .